Thursday, February 25, 2021

Financial News Conference on the Full Year 2020 Results

Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent)
EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management
Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth
Core earnings per share at 6.39 euros (plus 0.2 percent)
Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments
Net financial debt improves by 11.8 percent to 30.041 billion euros
Proposed dividend of 2.00 euros per share (2019: 2.80 euros)
Portfolio and innovation capabilities strengthened
Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies